Crosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer
Open Access
- 1 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Colorectal cancer (CRC) is often characterized by mutations and aberrant DNA methylation within the promoters of tumor suppressor genes and proto-oncogenes. The most frequent somatic mutations occur within KRAS and BRAF genes. Mutations of the KRAS gene have been detected in approximately 40% of patients, while mutations in BRAF have been detected less frequently at a rate of 10%. In this study, the DNA methylation levels of 22 candidate genes were evaluated in three types of tissue: mucosal tumoral tissue from 18 CRC patients, normal adjacent tissues from 10 CRC patients who underwent surgical resection, and tissue from a control group of six individuals with normal colonoscopies. A differential methylation profile of nine genes (RUNX3, SFRP1, WIF1, PCDH10, DKK2, DKK3, TMEFF2, OPCML, and SFRP2) presenting high methylation levels in tumoral compared to normal tissues was identified. KRAS mutations (codons 12 or 13) were detected in eight CRC cases, and BRAF mutations (codon 600) in four cases. One of the CRC patients presented concomitant mutations in KRAS codon 12 and BRAF, whereas seven patients did not present these mutations (WT). When comparing the methylation profile according to mutation status, we found that six genes (SFRP2, DKK2, PCDH10, TMEFF2, SFRP1, HS3ST2) showed a methylation level higher in BRAF positive cases than BRAF negative cases. The molecular sub-classification of CRC according to mutations and epigenetic modifications may help to identify epigenetic biomarkers useful in designing personalized strategies to improve patient outcomes.Keywords
Funding Information
- Ministry of Education and Research, Romania
This publication has 42 references indexed in Scilit:
- Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomasBMC Cancer, 2013
- DNA methylation as an epigenetic biomarker in colorectal cancerOncology Letters, 2013
- Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancerJournal of Cancer Research and Clinical Oncology, 2012
- Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategiesDrug Resistance Updates, 2011
- Novel Application of Structural Equation Modeling to Correlation Structure Analysis of CpG Island Methylation in Colorectal CancerThe American Journal of Pathology, 2010
- Aberrant Gene Promoter Methylation Associated with Sporadic Multiple Colorectal CancerPLOS ONE, 2010
- Function and biological roles of the Dickkopf family of Wnt modulatorsOncogene, 2006
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988
- The Effect of β-Blockade on Platelet Function and Fibrinolytic ActivityJournal of Cardiovascular Pharmacology, 1987
- Hypomethylation distinguishes genes of some human cancers from their normal counterpartsNature, 1983